Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis

Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis

IntroductionVulvar cancer carries a favourable prognosis in early stages. However, therapeutic options for advanced or recurrent cases are limited despite a variety of therapeutic modalities, such as extensive surgical resection, chemotherapy, and radiotherapy. The most important emerging treatment...

Full description

Bibliographic Details
Main Authors:	Roxana Schwab, Lina Judit Schiestl, Lorena Cascant Ortolano, Philip Herbert Klecker, Mona Wanda Schmidt, Katrin Almstedt, Anne-Sophie Heimes, Walburgis Brenner, Kathrin Stewen, Marcus Schmidt, Annette Hasenburg
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Oncology
Subjects:	vulvar cancer PD-L1 PD-1 pembrolizumab immune checkpoint inhibitor meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1352975/full

Similar Items

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
by: Takuma Isshiki, et al.
Published: (2018-10-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report
by: Ali McBride, et al.
Published: (2021-07-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2017-06-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
by: Nicolas A. Giraldo, et al.
Published: (2018-10-01)

A case of long-term complete remission of locally advanced T4 bladder cancer treated with pembrolizumab
by: Yuki Horibe, et al.
Published: (2022-03-01)

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
by: Simiao Wang, et al.
Published: (2023-06-01)

Pembrolizumab‐induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient
by: Anthony D. Honigman, et al.
Published: (2019-04-01)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
by: Qu J, et al.
Published: (2020-07-01)

Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
by: Tae‐Hun Kim, et al.
Published: (2021-12-01)

Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab
by: Carmen Navarro-Perea, et al.
Published: (2019-01-01)

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
by: Lu Si, et al.
Published: (2022-10-01)

Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report
by: Xiaoli Wu, et al.
Published: (2020-12-01)

Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
by: Anna E. Protasova, et al.
Published: (2021-08-01)

Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
by: Alessio Cirillo, et al.
Published: (2024-04-01)

Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
by: Jing Nie, et al.
Published: (2024-01-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV
by: Carmela Pinnetti, et al.
Published: (2022-05-01)

Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review
by: Alessandro Cafaro, et al.
Published: (2020-08-01)

Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial
by: Hyung Jun Park, et al.
Published: (2022-07-01)

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
by: du Rusquec P, et al.
Published: (2019-05-01)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
by: Elizabeth Dudnik, et al.
Published: (2021-01-01)

Case report: Local cryoablation combined with pembrolizumab to eliminate lung metastases from ovarian clear cell carcinoma
by: Liangliang Meng, et al.
Published: (2022-11-01)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022-08-01)

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
by: Camilo Jimenez, et al.
Published: (2020-08-01)

Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer
by: Lin Zhang, et al.
Published: (2020-11-01)

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
by: Gang Liu, et al.
Published: (2021-08-01)

Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study
by: Mei Zhan, et al.
Published: (2022-03-01)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022-01-01)

microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1
by: Kexin Jiang, et al.
Published: (2022-01-01)

Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
by: Tamkin Ahmadzada, BE, et al.
Published: (2020-11-01)

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
by: Evidio Domingo-Musibay, et al.
Published: (2018-06-01)

Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles
by: Moira Graves, et al.
Published: (2019-05-01)

Pulmonary large cell carcinoma, highly positive for PD‐L1, shows marked response to pembrolizumab: A case report
by: Naoyuki Okabe, et al.
Published: (2021-04-01)

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer
by: Ivy Riano, et al.
Published: (2021-07-01)

Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial
by: Susanne Wiegand, et al.
Published: (2023-03-01)

A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
by: Tao Li, et al.
Published: (2024-02-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01)